NCT07407439Recruiting
Real-world Studies of CDK4/6 Inhibitors
A Real-world Study on the Treatment of HR+/HER2- Advanced Breast Cancer Patients With CDK4/6 Inhibitors and Treatment Options After Drug Resistance.
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 245 (estimated)
- First submitted
- 5 Feb 2026
- Start date
- 1 Jun 2025
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07407439
What you commit to
- Study type: Observational
- Planned participants: 245
- From 1 Jun 2025 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Only received CDK4/6 inhibitors monotherapy.
- Received CDK4/6 inhibitors as neoadjuvant/postoperative adjuvant intensification therapy.
Other
- Incomplete medical history data.
Who the study is looking for
- Age ≥ 18 years old;
- Patients diagnosed with HR+/HER2- (as defined by the ASCO/CAP guidelines) advanced breast cancer who were treated in our hospital from March 2022 to March 2025;
- Received CDK4/6 inhibitors (including but not limited to the four currently marketed ones: palbociclib, abemaciclib, ribociclib, and dalpiciclib) as advanced-stage treatment for at least one cycle;
- Have complete medical history records, including demographic information, pathological reports, treatment records, laboratory test results, and imaging examination reports, etc.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University Cancer Insititute and Hospital Coordinator of this site? Confirm its status | Tianjin | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.